| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3195 | 2013 |
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial B Escudier, A Pluzanska, P Koralewski, A Ravaud, S Bracarda, C Szczylik, ... The Lancet 370 (9605), 2103-2111, 2007 | 2896 | 2007 |
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology 26 (7), 1148-1159, 2008 | 2429 | 2008 |
| Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial E Basch, AM Deal, MG Kris, HI Scher, CA Hudis, P Sabbatini, L Rogak, ... Journal of Clinical Oncology 34 (6), 557-565, 2016 | 2224 | 2016 |
| Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update BR Ferrell, JS Temel, S Temin, ER Alesi, TA Balboni, EM Basch, JI Firn, ... Journal of Clinical Oncology 35 (1), 96-112, 2017 | 1923 | 2017 |
| Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment E Basch, AM Deal, AC Dueck, HI Scher, MG Kris, C Hudis, D Schrag Jama 318 (2), 197-198, 2017 | 1917 | 2017 |
| American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care TJ Smith, S Temin, ER Alesi, AP Abernethy, TA Balboni, EM Basch, ... Journal of clinical oncology 30 (8), 880-887, 2012 | 1548 | 2012 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1340 | 2016 |
| Antiemetics: American Society of Clinical Oncology clinical practice guideline update E Basch, AA Prestrud, PJ Hesketh, MG Kris, PC Feyer, MR Somerfield, ... Journal of Clinical Oncology 29 (31), 4189-4198, 2011 | 994 | 2011 |
| Antiemetics: American Society of Clinical Oncology clinical practice guideline update PJ Hesketh, MG Kris, E Basch, K Bohlke, SY Barbour, RA Clark-Snow, ... Journal of Clinical Oncology 35 (28), 3240-3261, 2017 | 919* | 2017 |
| Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) E Basch, BB Reeve, SA Mitchell, SB Clauser, LM Minasian, AC Dueck, ... Journal of the National Cancer Institute 106 (9), dju244, 2014 | 887 | 2014 |
| Therapeutic applications of fenugreek M Smith Alternative Medicine Review 8 (1), 20-27, 2003 | 878 | 2003 |
| Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) AC Dueck, TR Mendoza, SA Mitchell, BB Reeve, KM Castro, LJ Rogak, ... JAMA oncology 1 (8), 1051-1059, 2015 | 715 | 2015 |
| Bitter melon (Momordica charantia): a review of efficacy and safety E Basch, S Gabardi, C Ulbricht American Journal of Health-System Pharmacy 60 (4), 356-359, 2003 | 698 | 2003 |
| The missing voice of patients in drug-safety reporting E Basch New England Journal of Medicine 362 (10), 865-869, 2010 | 694 | 2010 |
| Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension M Calvert, D Kyte, R Mercieca-Bebber, A Slade, AW Chan, MT King, ... Jama 319 (5), 483-494, 2018 | 691 | 2018 |
| Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study E Basch, A Iasonos, T McDonough, A Barz, A Culkin, MG Kris, HI Scher, ... The lancet oncology 7 (11), 903-909, 2006 | 663 | 2006 |
| Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes E Basch, X Jia, G Heller, A Barz, L Sit, M Fruscione, M Appawu, A Iasonos, ... JNCI: Journal of the National Cancer Institute 101 (23), 1624-1632, 2009 | 662 | 2009 |
| The PCORI perspective on patient-centered outcomes research L Frank, E Basch, JV Selby, ... Jama 312 (15), 1513-1514, 2014 | 578 | 2014 |
| Recommendations on evidence needed to support measurement equivalence between electronic and paper‐based patient‐reported outcome (PRO) measures: ISPOR ePRO Good Research … SJ Coons, CJ Gwaltney, RD Hays, JJ Lundy, JA Sloan, DA Revicki, ... Value in Health 12 (4), 419-429, 2009 | 577 | 2009 |
Michael J. MorrisMemorial Sloan-Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
